Discovery and clinical introduction of first-in-class imipridone ONC201

ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC2...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342060/
https://ncbi.nlm.nih.gov/pubmed/27602582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11814
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky